{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:35:00Z","timestamp":1788305700290,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The purpose was to clarify the characteristics of interstitial lung disease (ILD) in immune-mediated necrotizing myopathy (IMNM) patients with anti-signal recognition particle (SRP) antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical records of IMNM patients with anti-SRP antibodies were reviewed retrospectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 60 patients were identified. Twenty-seven (45.0%) patients were diagnosed with ILD based on lung imaging: nonspecific interstitial pneumonia (NSIP) in 17 patients (63.0%) and organizing pneumonia in 9 patients (33.3%). Reticulation pattern was identified in 17 patients (63.0%) whereas 10 cases (37.0%) showed ground glass opacity and patchy shadows by high-resolution computed tomography (HRCT). Pulmonary function tests (PFTs) were available in 18 patients, 6 (33.3%) and 10 (55.6%) patients were included in the mild and moderate group, respectively. The average age at the time of ILD onset was significantly older than those without ILD (48.6\u2009\u00b1\u200914.4\u00a0years vs. 41.2\u2009\u00b1\u200915.4\u00a0years,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), and the frequency of dysphagia in the ILD group was higher than the group without ILD (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Long-term follow-up was available on 9 patients. PFTs were stable in 8 (88.9%), and the HRCT remained stable in 6 (66.7%) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ILD is not rare in IMNM patients with anti-SRP antibodies, most being characterized as mild to moderate in severity. NSIP is the principal radiologic pattern, and ILD typically remains stable following treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12890-021-01802-1","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:02:46Z","timestamp":1641772966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies"],"prefix":"10.1186","volume":"22","author":[{"given":"Yongpeng","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"1802_CR1","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/0006-291X(82)91923-4","volume":"109","author":"Y Nakao","year":"1982","unstructured":"Nakao Y, Mukai R, Kabashima T, et al. A novel antibody which precipitates 7.5S RNA is isolated from a patient with autoimmune disease. Biochem Biophys Res Commun. 1982;109:1332\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1802_CR2","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.4049\/jimmunol.138.10.3219","volume":"138","author":"N Okada","year":"1987","unstructured":"Okada N, Mimori T, Mukai R, et al. Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol. 1987;138:3219\u201323.","journal-title":"J Immunol"},{"key":"1802_CR3","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","volume":"83","author":"WH Reeves","year":"1986","unstructured":"Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A. 1986;83:9507\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1802_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","volume":"20","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20:21.","journal-title":"Curr Rheumatol Rep"},{"key":"1802_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017;44:1051\u20137.","journal-title":"J Rheumatol"},{"key":"1802_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11926-018-0798-1","volume":"20","author":"S Moghadam-Kia","year":"2018","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R. Anti-MDA5 antibody spectrum in western world. Curr Rheumatol Rep. 2018;20:78.","journal-title":"Curr Rheumatol Rep"},{"key":"1802_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","volume":"10","author":"S Suzuki","year":"2015","unstructured":"Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015;10:61.","journal-title":"Orphanet J Rare Dis"},{"key":"1802_CR8","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2169\/internalmedicine.0303-17","volume":"57","author":"T Kusumoto","year":"2018","unstructured":"Kusumoto T, Okamori S, Masuzawa K, et al. Development of necrotizing myopathy following interstitial lung disease with anti-signal recognition particle antibody. Intern Med. 2018;57:2045\u20139.","journal-title":"Intern Med"},{"key":"1802_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00296-009-1059-4","volume":"30","author":"F Wantke","year":"2010","unstructured":"Wantke F, Kneussl M, Hubner M, et al. Signal recognition particle (SRP) positive myositis in a patient with cryptogenic organizing pneumonia (COP). Rheumatol Int. 2010;30:1361\u20135.","journal-title":"Rheumatol Int"},{"key":"1802_CR10","first-page":"e7962","volume":"12","author":"A Qureshi","year":"2020","unstructured":"Qureshi A, Brown D, Brent L. Anti-signal recognition particle antibody-associated severe interstitial lung disease requiring lung transplantation. Cureus. 2020;12:e7962.","journal-title":"Cureus"},{"key":"1802_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"1802_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.resinv.2019.12.003","volume":"58","author":"N Aiko","year":"2020","unstructured":"Aiko N, Yamakawa H, Iwasawa T, et al. Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease. Respir Investig. 2020;58:196\u2013203.","journal-title":"Respir Investig"},{"key":"1802_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684\u201391.","journal-title":"Ann Intern Med"},{"key":"1802_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, et al. Antimelanoma diferentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol. 2017;44:319\u201325.","journal-title":"J Rheumatol"},{"key":"1802_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"1802_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/17476348.2020.1767598","volume":"14","author":"J Bermudez","year":"2020","unstructured":"Bermudez J, Heim X, Bertin D, et al. Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series. Expert Rev Respir Med. 2020;14:845\u201350.","journal-title":"Expert Rev Respir Med"},{"key":"1802_CR17","doi-asserted-by":"publisher","first-page":"106309","DOI":"10.1016\/j.rmed.2021.106309","volume":"178","author":"M Baqir","year":"2021","unstructured":"Baqir M, Vasirreddy A, Vu AN, et al. Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a population-based, case\u2013control study. Respir Med. 2021;178:106309.","journal-title":"Respir Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-021-01802-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T10:11:48Z","timestamp":1674382308000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01802-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1802"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01802-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"18 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Review Committee (RRC) and the Ethical Review Committee (ERC) of the China-Japan Friendship Hospital (IRB number is 2016-117). In the retrospective non-interventional study, all patients\u2019 data was anonymously used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}